Literature DB >> 17341150

Evaluation of subretinal triamcinolone acetonide in patients with exudative age-related macular degeneration.

Igor Kozak1, Lingyun Cheng, Iryna Falkenstein, Ajay M Tammewar, William R Freeman.   

Abstract

PURPOSE: The aim of this paper was to present the results of subretinal delivery of triamcinolone acetonide (TCA) in humans with choroidal neovascularization (CNV) caused by age-related macular degeneration (AMD).
METHODS: Twenty two (22) eyes of 22 patients underwent pars plana vitrectomy with subretinal TCA administration. Two milligrams (2 mg) of preservative-free TCA were delivered through a 32-gauge automatic subretinal injector in 20 microL of volume. Visual acuity, fluorescein angiography (FA), and intraocular pressure (IOP) were recorded and compared pre- and postoperatively.
RESULTS: Preoperative average+/-standard deviation visual acuity in the treated eye was 1.408+/-0.129 (logMAR; median 20/400) and 1.403+/-0.114 (logMAR; median 20/300) postoperatively (P=0.51). The mean area of pre- and postoperative FA leakage in the operated eyes was 21.31+/-1.125 and 19.29+/-1.108 mm2, respectively (P=0.04). The average IOP value before treatment was 15.3+/-0.78 mmHg. Three (3) months after surgery, it was 20.5+/-2.04 mmHg (P=0.02). Six (6) months and 1 year after surgery, the average IOP was 17.0+/-0.66 mmHg (P=0.9) and 15.6+/-1.02 mmHg (P=0.6), respectively.
CONCLUSIONS: Subretinal TCA stabilizes visual acuity, decreases FA leakage in eyes with CNV owing to AMD, and does not increase IOP, as seen with intravitreous injections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17341150     DOI: 10.1089/jop.2006.0092

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  1 in total

1.  Natural history of sub-retinal triamcinolone acetonide deposition after triamcinolone-assisted vitrectomy.

Authors:  Raju Sampangi; Pradeep Venkatesh; Sat Pal Garg
Journal:  Int Ophthalmol       Date:  2007-09-26       Impact factor: 2.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.